ClinicalTrials.gg
Not yet recruitingNCT06094309Updated Oct 23, 2023

Effectiveness of Botulinum Toxin in Freezing of Gate in Parkinson's Disease Walking in Parkinson's Disease.

An interventional study of Botulinum toxin type A injection in Freezing of Gate, Parkinson Disease and Botulinum Toxin, sponsored by Centro Hospitalar de Lisboa Central. Not yet recruiting at 1 site in Portugal. Per ClinicalTrials.gov, last updated 2023-10-23.

Sponsored by Centro Hospitalar de Lisboa Central · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Parkinson Disease with a site in Portugal — 4 open to participants now, 5 under way, 2 of them phase 3. Parkinson Disease · Portugal.

Planned enrollment
41st of 51
20 · median 106
Started
2024
the only one that year
No phase
9 of 55
2 open now
Registered
51st of 55
by date

Among the 55 studies in Parkinson Disease with a site in Portugal, this one is the 41st largest by planned enrollment of the 51 interventional ones that give a count, is the only one that started in 2024, is one of 9 with no phase, and was the 51st registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

4 of the 55 studies in Parkinson Disease with a site in Portugal are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Parkinson Disease with a site in Portugal, or all of them as a file.
02

Study summary

Freezing of gait is a symptom of Parkinson's disease (PD) that becomes more evident with the evolution of the disease, and which presents an important difference compared to the other signs and symptoms: does not respond adequately to dopaminergic therapy, which calls into question its pathophysiology. In this sense, and through empirical experience, it has been noted that freezing responds to cueing techniques (visual, sensory motor, auditory tricks, among others) which suggests a similarity with dystonic pathology. This similarity could be the basis of a common response to botulinum toxin (BT). Objectives: This study aims to understand whether BT is an effective therapy for freezing gait in patients with Parkinson's disease. Methodology: This is a prospective parallel study with therapeutic intervention, controlled by placebo, double blind. The randomization of groups will be stratified. The population will be recruited from from the CHLC movement disorders consultation, and that meets the following inclusion criteria: Parkinson's disease with freezing of gait, scoring > 1 at point 2.13 on the scale MDS-UPDRS and be responsive to cueing techniques, with severity of Parkinson's disease rated 3 or 4 on the Hoehn \& Yahr scale. The BT injection will be performed by a doctor with experience in this therapy, with 100 Units (U) of type A BT, bilaterally, in the flexor muscle of the thigh, once, with replacement of the same ampoules with saline in controls. To the Patient assessments will take place over 4 months, weekly by telephone using a questionnaires on freezing and the notion of clinical improvement (FOGQ and SCGIC, respectively) and monthly in person with objective assessments using the MDS-UPDRS scales - part III motor assessment, Timed Up \& Go and Two Minute Walk.

Read the detailed description

Study with therapeutic intervention, placebo-controlled, double-blind, with stratified randomization using the minimization method. The variables to consider by this method will be binary variables and three will be considered: the severity of the freezing (degree 2 freezing / degree 3 and 4 freezing)8, the severity of the disease Parkinson's (Hoehn \& Yahr (H\&Y) stage 3 / H\&Y stage 4)9 and cognitive capacity (Mini-Mental State Examination (MMSE) 10-23 / MMSE 24-30)10.

People with Parkinson's disease in advanced stages, with freezing of gait frequent, responsive to cueing techniques, followed in consultation for diseases of the movement at CHULC, with the participation of doctors specializing in diseases of movement. All eligible participants will be required to complete the consent informed prior to their inclusion in the study.

Inclusion criteria: people with idiopathic Parkinson's disease with the presence of gait freezing, which scores > 1 at point 2.13 of the MDS-UPDRS8 scale and is responsive to cueing techniques, with severity of Parkinson's disease classified between 3 and 4 on the Hoehn \& Yahr9 scale.

Exclusion criteria: previous exposure to toxin therapy, alteration of therapy for PD during the course of the study, cognitive impairment with MMSE10 \< 10.

There will be two distinct modalities of observation and assessment of patients: in person, every month for 4 months, with observation of the patient and application of MDS-UPDRS8 scale, Timed Up \& Go (TUG) scale11, and Two Minutes Walk scale12 and telephone, every week for 4 months, with the application of a questionnaire on the freezing and another about the impression of improvement. Both assessment modalities will be carried out by doctors from the Neurology service.

  1. Observation of the patient before administration of BT therapy and every month, on a scheduled basis, at the same time, 12 hours after suspension of the levodopa therapy (T0, T1M, T2M, T3M, T4M) and classification of scales Timed Up \& Go11 and Two Minutes Walk12;
  2. Application of the FOGQ13 and SCGIC14 questionnaires before administration of the therapy and every week, via telephone, to the patient (T0, T1S, T2S, T3S, T1M, T5S, T6S, T7S, T2M, T9S, T10S, T11S, T3M, T13S, T14S, T15S, T4M).
03

Conditions studied

  • Freezing of Gate
  • Parkinson Disease
  • Botulinum Toxin

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: people with idiopathic Parkinson's disease with the presence of gait freezing, which scores > 1 at point 2.13 of the MDS-UPDRS8 scale and is responsive to cueing techniques, with severity of Parkinson's disease classified between 3 and 4 on the Hoehn \& Yahr9 scale.

Exclusion Criteria: previous exposure to toxin therapy, alteration of therapy for PD during the course of the study, cognitive impairment with MMSE10 \< 10.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
20 participants (estimated)

Study arms

  • Active comparator
    Active Comparator: botulinum toxin

    The botulinum toxin injection will be carried out by a doctor with experience in this therapeutic modality, which in turn is not part of the group of doctors who observe patients in the initial and subsequent phases. 100 Units (U) of botulinum toxin type A, in each lower limb (200 U in total), in muscle proximal thigh, once, at a moment that will be defined as T0. This group of 10 participans.

    Drug: Botulinum toxin type A injection

  • Placebo comparator
    Active Comparator: Placebo

    In the control group, patients will be subject to the same protocol, with the difference in that the injections will be saline, although they look the same on the outside. You doctors carrying out therapy and evaluating progress during face-to-face visits will not have access to the distribution of groups. This group of 10 participans.

    Drug: Botulinum toxin type A injection

Interventions

  • DrugBotulinum toxin type AStudies of Botulinum toxin type ABotulinum toxin type A pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The BT injection will be performed by a doctor with experience in this therapy, with 100 Units (U) of type A BT, bilaterally, in the flexor muscle of the thigh, once, with replacement of the same ampoules with saline in controls. To the Patient assessments will take place over 4 months, weekly by telephone using a questionnaires on freezing and the notion of clinical improvement (FOGQ and SCGIC, respectively) and monthly in person with objective assessments using the MDS-UPDRS scales - part III motor assessment, Timed Up \& Go and Two Minute Walk.

06

What researchers measure

Primary outcomes

  1. Variation Unified Parkinson's Disease Rating Scale (MDS-UPDRS8)

    which is defined as fever (auricular temperature \>38ºC) and elevation of CRP (\> 75 mg/L), during the first 3 days after operation.

    Time frame: for 4 months after the study

  2. Variation Escala "Timed Up & Go"11

    20% improvement in completion time in any reevaluations;

    Time frame: for 4 months after the study

  3. Variation Escala Two Minutes Walk12

    20% improvement in the distance covered in any reevaluations;

    Time frame: for 4 months after the study

07

Study locations

1 site
  • Maria Margarida Grilo da Silva Dias
    Lisboa, 1150-199, Portugal
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2024; primary completion for Jun 2024, 0 months later.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 0 months is below that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2023
First posted
Oct 23, 2023
StartEst.
Jun 1, 2024
Primary completionEst.
Jun 30, 2024
CompletionEst.
Jun 30, 2025
Last update
Oct 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06094309
Lead sponsor
Centro Hospitalar de Lisboa Central
Responsible party
Sponsor
First posted
Oct 23, 2023
Start date
Jun 1, 2024 (estimated)
Primary completion
Jun 30, 2024 (estimated)
Completion
Jun 30, 2025 (estimated)
Last update
Oct 23, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion